PBYI Puma Biotechnology, Inc.: Earnings per share for the last 12 months

Puma Biotechnology Inc (PBYI) - corporate logo

Puma Biotechnology (PBYI) business relies on non-cyclical demand in the targeted therapy segment, where success depends on the expansion of indications for the drug Nerlynx. The inclusion of the drug Inertia in global treatment protocols ensures stable revenues. This chart of EPS value changes on GURU.Markets, reaching -36.40, is complemented by the implementation of cloud AI for accelerated biomedical data processing and the automation of clinical trials.

Puma Biotechnology Inc (PBYI) Net earnings per share (EPS TTM): for the period 02/11/2024 - 11/10/2026

PBYI (Puma Biotechnology Inc): analytical breakdowns and indicator data

- current quotes and average value forecast:
Stock Price Puma Biotechnology|PBYI - Price Target Chart
- company stock capitalization data:
Market Capitalization Puma Bio|PBYI - Enterprise Value
- book capitalization indicators:
Accounting Value per Share Puma Biotechnology|PBYI - Book Capitalization|Market-to-Book Ratio pumabiotechnology.com|PBYI - Aggregate Company Assets
- company total debt and liquidity indicators:
All Debt to Shareholders' Equity Ratio Puma Biotechnology|PBYI - Long-Term Debt to Equity|Current Liabilities to Equity Puma Biotechnology|PBYI - Company Total Debt|Debts to Book Capitalization Puma Bio|PBYI - Company Long-Term Debt|Company Current Liabilities Puma Biotechnology|Quick Ratio pumabiotechnology.com
- earnings and market multiples details:
PBYI - Net Income|Expected Net Income Puma Biotechnology|PBYI - P/E Multiple|Future Price to Earnings Puma Biotechnology|PBYI - PEG Multiple|Total Company Value to Operating Income Before Depreciation Ratio Puma Bio|PBYI - Profit before payment of interest, taxes and amortization|Net earnings per one share for the last twelve months Puma Biotechnology|PBYI - Net earnings per share for the last 12 months|Year-over-year earnings per share growth rate for the last twelve months pumabiotechnology.com|PBYI - Earnings growth in current year|Expected net earnings per share growth next year Puma Biotechnology
Fundamental valuation:PBYI - Puma Biotechnology, Inc.
Product sample of Puma Biotechnology Inc

Year-over-year (TTM) EPS growth measures the percentage change in net income per share over twelve months, reflecting the efficiency of business capitalization. By analyzing the EPS YoY TTM trend, an investor sees the current value of -36.40, which allows for an assessment of the company's ability to scale profitability. This metric discounts the actual profitability of developments amid market volatility. The specific sovereign product cycle of Puma Biotechnology (PBYI) ensures the stability of this indicator regardless of global macroeconomic fluctuations.

Competitor analysis

OLMA - Net earnings per share (EPS TTM)|Greenwich LifeSciences, Inc. (GLSI) - Earnings per share for the last twelve months|Earnings per share for the last 12 months ZNTL|MGNX (MacroGenics Corp) - Net earnings per share (EPS TTM)|Net earnings per share for the last 12 months Cytori Therapeutics (PSTV)|Net earnings per share (EPS TTM) PCSA|EGRX - Net earnings per one share for the last twelve months